Document |
Document Title |
JP2006505115A |
The present invention relates to charge transport compositions. The invention further relates to electronic devices in which there is at least one active layer comprising such charge transport compositions.
|
JP2006501201A |
Compounds, compositions and methods useful for treating cellular proliferative diseases and disorders, for example, by modulating the activity of KSP, are disclosed.
|
JP2006501306A |
Compounds, compositions and methods useful for treating cellular proliferative diseases and disorders, for example, by modulating the activity of KSP, are disclosed.
|
JP2001519366A5 |
|
JP3725158B2 |
A method of treating asthma in a subject in need of such treatment is disclosed. The method comprises administering to the subject dehydroepiandrosterone, analogs thereof, or pharmaceutically acceptable salts thereof in an amount effecti...
|
JP2005536475A |
A method of modulating KSP kinesin activity in vitro comprising contacting KSP kinesin with at least one chemical entity chosen from compounds represented by Formula I: and pharmaceutically acceptable salts thereof, where the variables a...
|
JP2005533139A |
The present invention relates to charge transport compositions. The invention further relates to electronic devices in which there is at least one active layer comprising such charge transport compositions.
|
JP2005533343A |
The present invention relates to charge transport compositions. The invention further relates to electronic devices in which there is at least one active layer comprising such charge transport compositions.
|
JP2005306880A |
To obtain a prophylactic drug for treatment of asthma or bronchoconstriction in a patient necessitating treatment for adenosine depletion.This invention relates to the prophylactic drug for treatment of asthma or bronchoconstriction of h...
|
JP2005533342A |
The present invention relates to charge transport compositions. The invention further relates to electronic devices in which there is at least one active layer comprising such charge transport compositions.
|
JP2005533341A |
The present invention relates to charge transport compositions. The invention further relates to electronic devices in which there is at least one active layer comprising such charge transport compositions.
|
JP3699760B2 |
To obtain a compound in a mild condition and in high yield by using a safe hydrazine and an azo derivative compound as raw materials. This compound is obtained by carrying out a coupling reaction of a compound of formula I (Z1 is an acyl...
|
JP2005247864A |
To provide a method for treating or preventing neuron loss, neurodegenerative diseases, and the injurious effects of excitatory amino acid overstimulation.This medicinal composition contains a compound represented by formula [R4, R5 and ...
|
JP2005519912A |
Compounds of the general formula (I) and their acid addition salts are provided wherein: R<1 >signifies a piperazino, p-phenylenediamino, a 2,5-diazabicyclo-[2.2.1]-heptane, a 2,5-diazabicyclo-[2.2.2]-octane radical or a 3,8-diazabicyclo...
|
JPWO2003075935A1 |
Using at least one of riboflavin, riboflavin derivative, or a pharmacologically acceptable salt thereof as an active ingredient, IL-1β, IL-6, IL-10, INF-γ, TNF-α, GM-CSF, IL To provide a drug having an action of suppressing cytokines ...
|
JP2005516927A |
Compounds of formula (I) are useful for inhibiting protein kinases and treating cancer. Compositions that inhibit protein kinases and methods of inhibiting protein kinases in patients are also disclosed. [Chemical 1]
|
JP2005516005A |
The present invention provides a compound of formula (I): (I), or a pharmaceutically acceptable derivative thereof. These compounds are inhibitors of protein kinases, particularly inhibitors of GSK-3 mammalian protein kinases. The invent...
|
JP2005139134A |
To obtain a new folic acid derivative compound exhibiting excellent functions by the self-organization of the molecule.This folic acid derivative compound is represented by formula (1) (wherein, R1 is a 5-20C linear hydrocarbon group; R2...
|
JP2005508983A |
The invention relates to the combined administration of a PDE4 or PDE3/4 inhibitor and a disease modifying anti-rheumatic drug (DMARDs) or anti-rheumatic or anti-arthritic drug.
|
JP3636207B2 |
PURPOSE: To provide an immune-activating and infection-preventing agent safe for men and animals, and also to provide a method for producing the same. CONSTITUTION: An immune-activating and infection-preventing agent comprises riboflavin...
|
JP2005082523A |
To provide a memantine medication solving the problem of Alzheimer's disease and Parkinson's disease not being fundamentally cured because of unknown causes, and achieving excellent therapeutic effects though the reasons are uncertain.Th...
|
JP2005507390A |
The invention provides certain pteridinone compounds of formula (I), processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.
|
JP2005015417A |
To provide a composition having antifatigue effects, treating clonic fatigue syndrome and preventing death by overwork.The composition contains a biopterin-related material, e.g. biopterin (2-amino-4-hydroxy-6-[1,2-dihydroxypropyl]pterid...
|
JP2004537551A |
A method for treating neoplastic, angiogenic, fibroblastic, and/or immunosuppressive ocular irregularities of a living subject, comprising the steps of: providing a living subject, wherein the living subject includes an affected ocular a...
|
JP3599287B2 |
PURPOSE: To obtain a new sulfonamide derivative exhibiting strong inhibiting action against cysteine protease such as calpain, cathepsin B, cathepsin H, cathepsin L and papain. CONSTITUTION: A sulfonamide derivative expressed by the form...
|
JP3560377B2 |
PURPOSE: To obtain a catalyst promoting hydrogenation under low temp. and low hydrogen pressure reaction conditions by using a Raney ruthenium catalyst as a catalyst for hydrogenating a part showing aromatic properties contained in a mol...
|
JPWO2002051797A1 |
The following general formula (I) (in the formula, A is, B is, R is H, NO2, NH2, NHCbz, Br, F, Cl or SO3Na2, and n is an integer of 1 to 4). A method for producing the compound, which comprises reacting the active ester with a t-butoxyca...
|
JP3556689B2 |
Substantially dry micronutrient compositions comprise up to 15% by weight of a micronutrient, a binding amount of a binder, and a densifying amount of a densifying agent of particle size from approximately 40 mesh to approximately 325 me...
|
JP2004203751A |
To provide an corticotropin releasing factor (hormone) CRF (CRH) antagonist useful for Alzheimer's disease and obesity.The substituted 6,6-heterobicyclic derivative is represented by formula I [wherein, A denotes an N or a CR7, B denotes...
|
JP2004512255A |
This invention relates to novel multibinding compounds (agents) that are antibacterial agents. The multibinding compounds of the invention comprise from 2-10 ligands covalently connected by a linker or linkers, wherein each of said ligan...
|
JP2004509115A |
This invention describes novel triazole compounds of formula IX: wherein Z1 is nitrogen or CR9 and Z2 is nitrogen or CH, provided that at least one of Z1 and Z2 is nitrogen; G is Ring C or Ring D; Ring C is selected from a phenyl, pyridi...
|
JP2004509118A |
This invention describes novel triazole compounds of formula IX: wherein Z1 is nitrogen or CR9 and Z2 is nitrogen or CH, provided that at least one of Z1 and Z2 is nitrogen; G is Ring C or Ring D; Ring C is selected from a phenyl, pyridi...
|
JP2004509139A |
The invention relates to the use of riboflavin and of flavin derivatives with chitinase-inhibitory action for controlling arthropods, nematodes and chitin-containing fungi.
|
JP2003535123A |
This invention pertains to active barbituric acid analogs which inhibit HIF-1 activity (e.g., the interaction between HIF-1$g(a) and p300) and thereby inhibit angiogenesis, tumorigenesis, and proliferative conditions, such as cancer. The...
|
JP2003533480A |
The present invention describes a method for programming a specific course and rate of metabolism for a parent drug compound that leads to an inactive or very weakly active and nontoxic metabolite when the modified drug compound is admin...
|
JP2003532655A |
Compositions are proposed which comprise folic acid in combination with 5-methyltetrahydrofolic acid, and also compositions which comprise folic acid, 5-methyltetrahydrofolic acid and/or 5-methyltetrahydrofolylpolyglutamate and also comp...
|
JP2003532674A |
The present invention relates to the use of lipoic acid and C1 donors, in particular S-adenosylmethionine and/or 5-methyltetrahydrofolate, for the treatment of central nervous system disorders, to compositions with a corresponding active...
|
JP2003292441A |
To provide a radiation sensitizer.The agent contains a pterin derivative of formula I, its cyclized compound or their salts. In formula I, R1 and R2 are each a 1-20C alkyl optionally substituted with one or more groups selected from OH, ...
|
JP3455180B2 |
The invention provides a compound of formula (I) wherein X, R1, R2 and Het are as defined in the description, and a process for preparing them. The compounds of formula (I) are useful as pharmaceuticals.
|
JP2003238409A |
To provide an immunosuppressant.The immunosuppressant comprises a pterin derivative represented by formula (I) [R1 and R2 are each a 1-20C alkyl group which may be substituted with one or more groups selected from a group consisting of O...
|
JP3440469B2 |
Specified phenylalanine derivatives and analogues thereof have an antagonistic activity to alpha 4 integrin. They are used as therapeutic agents for various diseases concerning alpha 4 integrin.
|
JP2003523933A |
Composition and formulations comprising a first agent such as folinic acid, pharmaceutically acceptable salts thereof or mixtures thereof, and a second agent(s) such as analgesics, muscle relaxants, mood disorder agents, anti-inflammator...
|
JP2003524012A |
The invention provides pteridine compounds of formula (I), processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy. Formula (I) in which A is a group of formula (a) or (b).
|
JP3433301B2 |
PURPOSE: To obtain a new compound producible in high yield in easily purifiable state having extremely high crystallinity and, accordingly, practically usable as an agent for the treatment of side actions of a cancer-suppressing agent an...
|
JP2003520783A5 |
|
JP2003520843A |
The present invention refers to new classes of polymerisable monomers, to molecularly imprinted polymers obtainable by polymerisation of at least one of the monomers and a crosslinking monomer in the presence of a template molecule. The ...
|
JP3419585B2 |
PURPOSE: To provide the subject compound having high chemically and optically purity and excellent stability. CONSTITUTION: Crystalline (6S)-tetrahydrofolic acid and crystalline (6R)- tetrahydrofolic acid. The crystalline (6S)-tetrahydro...
|
JP3420549B2 |
To obtain an anticancer compound in a high yield useful for treating a highly proliferative disorder such as cancer in mammals by using a specific synthetic intermediate. (A) A compound of formula I [R1 and R2 are each a 1-10C alkyl, a 1...
|
JP2003512340A |
Methods are provided for neutralization of microorganisms in fluids or on surfaces. Preferably the fluids contain blood or blood products and comprise biologically active proteins. Preferred methods include the steps of adding an activat...
|
JP2003510327A |
This invention relates to novel compounds, compositions, and methods for the treatment of physiological disorders associated with an excess of neuropeptide Y. The novel compounds encompassed by the present invention are those of the form...
|